Biocodex’s €15m microbiome investment targets a major drug manufacturing bottleneck
Biocodex invests €15 million in French microbiome manufacturing, targeting clinical batches by 2028. Examine its scale-up strategy.
Biocodex invests €15 million in French microbiome manufacturing, targeting clinical batches by 2028. Examine its scale-up strategy.
Stereotaxis, Inc. has completed its acquisition of French vascular robotics developer Robocath, bringing together two different approaches to controlling medical devices during minimally invasive endovascular procedures. Robocath will be integrated into the United States-based surgical robotics company, which plans to combine its magnetic navigation technology with Robocath’s mechanically controlled platforms for interventional cardiology, neurointerventions and
VB Spine has begun shipping spine surgery products from its newly operational European distribution centre in Cestas, France, giving the privately held medical technology company a more direct logistics base for serving hospitals and clinical customers across the region. The facility, which started accepting orders on June 1, 2026, became fully operational in July and
See how Dassault Systèmes and PariSanté Campus could reshape sovereign healthcare AI in Europe. Read the industry analysis.
GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence